These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23518805)

  • 1. Tacrolimus salvage in anti-tumor necrosis factor antibody treatment-refractory Crohn's disease.
    Gerich ME; Pardi DS; Bruining DH; Kammer PP; Becker BD; Tremaine WT
    Inflamm Bowel Dis; 2013 May; 19(6):1107-11. PubMed ID: 23518805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic era.
    Thin LW; Murray K; Lawrance IC
    Inflamm Bowel Dis; 2013 Jun; 19(7):1490-8. PubMed ID: 23615528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of thalidomide in refractory Crohn's disease.
    Gerich ME; Yoon JL; Targan SR; Ippoliti AF; Vasiliauskas EA
    Aliment Pharmacol Ther; 2015 Mar; 41(5):429-37. PubMed ID: 25511905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up.
    Baumgart DC; Pintoffl JP; Sturm A; Wiedenmann B; Dignass AU
    Am J Gastroenterol; 2006 May; 101(5):1048-56. PubMed ID: 16573777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: a pilot study.
    González-Lama Y; Abreu L; Vera MI; Pastrana M; Tabernero S; Revilla J; Durán JG; Escartin P
    Inflamm Bowel Dis; 2005 Jan; 11(1):8-15. PubMed ID: 15674108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I; Faubion WA
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease.
    Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R
    Aliment Pharmacol Ther; 2002 Jun; 16(6):1117-24. PubMed ID: 12030953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506).
    Fellermann K; Ludwig D; Stahl M; David-Walek T; Stange EF
    Am J Gastroenterol; 1998 Oct; 93(10):1860-6. PubMed ID: 9772045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease.
    Ng SC; Arebi N; Kamm MA
    Inflamm Bowel Dis; 2007 Feb; 13(2):129-34. PubMed ID: 17206694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus Exerts Only a Transient Effectiveness in Refractory Pediatric Crohn Disease: A Case Series.
    Truffinet O; Martinez-Vinson C; Guerriero E; Hugot JP; Viala J
    J Pediatr Gastroenterol Nutr; 2017 May; 64(5):721-725. PubMed ID: 27429426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis.
    Watson S; Pensabene L; Mitchell P; Bousvaros A
    Inflamm Bowel Dis; 2011 Jan; 17(1):22-9. PubMed ID: 20722055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
    Colombel JF; Loftus EV; Tremaine WJ; Pemberton JH; Wolff BG; Young-Fadok T; Harmsen WS; Schleck CD; Sandborn WJ
    Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients.
    Protic M; Seibold F; Schoepfer A; Radojicic Z; Juillerat P; Bojic D; Mwinyi J; Mottet C; Jojic N; Beglinger C; Vavricka S; Rogler G; Frei P
    J Crohns Colitis; 2014 Nov; 8(11):1427-37. PubMed ID: 24908178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of tacrolimus (FK-506) on Japanese patients with refractory Crohn's disease.
    Tamaki H; Nakase H; Matsuura M; Inoue S; Mikami S; Ueno S; Uza N; Kitamura H; Kasahara K; Chiba T
    J Gastroenterol; 2008; 43(10):774-9. PubMed ID: 18958546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus.
    Tsukamoto H; Tanida S; Mizoshita T; Ozeki K; Ebi M; Shimura T; Mori Y; Kataoka H; Kamiya T; Joh T
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):714-8. PubMed ID: 23411870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease.
    Hoffmann P; Krisam J; Wehling C; Kloeters-Plachky P; Leopold Y; Belling N; Gauss A
    World J Gastroenterol; 2019 Aug; 25(31):4481-4492. PubMed ID: 31496626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab use in luminal Crohn's disease.
    Richter JA; Bickston SJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.
    Bortlik M; Duricova D; Malickova K; Machkova N; Bouzkova E; Hrdlicka L; Komarek A; Lukas M
    J Crohns Colitis; 2013 Oct; 7(9):736-43. PubMed ID: 23200919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.